| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007 [M. D. O., M. D. J., R. B. D., C-Y. L., B. S.]; Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom [M. S., J. F. S., H. G., G. C. S.]; and Department of Pathology, University of Edinburgh Medical School, Edinburgh EH8 9AG, United Kingdom [A. W., A. a-N.]
Purpose: Matriptase is a type II transmembrane serine protease expressed by cells of surface epithelial origin, including epithelial ovarian tumor cells. Matriptase cleaves and activates proteins implicated in the progression of ovarian cancer and represents a potential prognostic and therapeutic target. The aim of this study was to examine the expression of matriptase, and its inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), in epithelial ovarian cancer and to assign clinicopathological correlations.
Experimental Design: We have determined by immunohistochemistry the expression of matriptase and HAI-1 in 54 epithelial ovarian cancers. Statistical analyses of immunohistochemistry expression data with clinical outcome and clinicopathological parameters were then performed.
Results: Of 54 tumors tested, 39 (72%) and 11 (20%) were positive for matriptase and for HAI-1, respectively. All HAI-1-positive tumors were also matriptase positive. Analysis of clinicopathological parameters demonstrated a loss of matriptase associated with stage III/IV tumors as compared with stage I/II tumors (P = 0.030). There was also a loss of HAI-1 expression associated with stage III/IV tumors (P = 0.039). Of 34 stage I/II tumors, 28 (82%) stained positive for matriptase, and 10 (29%) stained positive for HAI-1; 10 (29%) tumors showed coexpression. Of 20 stage III/IV tumors, however, 11 stained positive for matriptase (55%), only 1 of which coexpressed HAI-1 (P = 0.039).
Conclusions: Advanced-stage ovarian tumors that express matriptase are more likely to do so in the absence of its inhibitor, HAI-1, indicating that an imbalance in the matriptase:HAI-1 ratio could be important in the development of advanced disease. Such an imbalance could promote the proteolytic activity of matriptase and, consequently, a more invasive phenotype.
This article has been cited by other articles:
|
|
 |
|
  I-C. Tseng, F.-P. Chou, S.-F. Su, M. Oberst, N. Madayiputhiya, M.-S. Lee, J.-K. Wang, D. E. Sloane, M. Johnson, and C.-Y. Lin Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1 Am J Physiol Cell Physiol, August 1, 2008; 295(2): C423 - C431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kojima, S. Tsuzuki, T. Fushiki, and K. Inouye Roles of Functional and Structural Domains of Hepatocyte Growth Factor Activator Inhibitor Type 1 in the Inhibition of Matriptase J. Biol. Chem., February 1, 2008; 283(5): 2478 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Lee, I-C. Tseng, Y. Wang, K.-i. Kiyomiya, M. D. Johnson, R. B. Dickson, and C.-Y. Lin Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain Am J Physiol Cell Physiol, July 1, 2007; 293(1): C95 - C105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Parr, A. J. Sanders, G. Davies, T. Martin, J. Lane, M. D. Mason, R. E. Mansel, and W. G. Jiang Matriptase-2 Inhibits Breast Tumor Growth and Invasion and Correlates with Favorable Prognosis for Breast Cancer Patients Clin. Cancer Res., June 15, 2007; 13(12): 3568 - 3576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Bhatt, A. Welm, C. J. Farady, M. Vasquez, K. Wilson, and C. S. Craik Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway PNAS, April 3, 2007; 104(14): 5771 - 5776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Seitz, S. Hess, H. Schulz, R. Eckl, G. Busch, H. P. Montens, R. Brandl, S. Seidl, A. Schomig, and I. Ott Membrane-Type Serine Protease-1/Matriptase Induces Interleukin-6 and -8 in Endothelial Cells by Activation of Protease-Activated Receptor-2: Potential Implications in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 769 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al. Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Netzel-Arnett, B. M. Currie, R. Szabo, C.-Y. Lin, L.-M. Chen, K. X. Chai, T. M. Antalis, T. H. Bugge, and K. List Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation J. Biol. Chem., November 3, 2006; 281(44): 32941 - 32945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, and D. Kirchhofer Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin J. Biol. Chem., October 13, 2006; 281(41): 30439 - 30446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Kiyomiya, M.-S. Lee, I-C. Tseng, H. Zuo, R. J. Barndt, M. D. Johnson, R. B. Dickson, and C.-Y. Lin Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells Am J Physiol Cell Physiol, July 1, 2006; 291(1): C40 - C49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saleem, V. M. Adhami, W. Zhong, B. J. Longley, C.-Y. Lin, R. B. Dickson, S. Reagan-Shaw, D. F. Jarrard, and H. Mukhtar A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 217 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fan, T. D. Wu, W. Li, and D. Kirchhofer Identification of Hepatocyte Growth Factor Activator Inhibitor-1B as a Potential Physiological Inhibitor of Prostasin J. Biol. Chem., October 14, 2005; 280(41): 34513 - 34520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. List, R. Szabo, A. Molinolo, V. Sriuranpong, V. Redeye, T. Murdock, B. Burke, B. S. Nielsen, J. S. Gutkind, and T. H. Bugge Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation Genes & Dev., August 15, 2005; 19(16): 1934 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Knudsen, J. M. Lucas, L. Fazli, S. Hawley, S. Falcon, I. M. Coleman, D. B. Martin, C. Xu, L. D. True, M. E. Gleave, et al. Regulation of Hepatocyte Activator Inhibitor-1 Expression by Androgen and Oncogenic Transformation in the Prostate Am. J. Pathol., July 1, 2005; 167(1): 255 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Lee, K.-i. Kiyomiya, C. Benaud, R. B. Dickson, and C.-Y. Lin Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells Am J Physiol Cell Physiol, April 1, 2005; 288(4): C932 - C941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tang, M. Kmet, L. Corral, S. Vartanian, A. Tobler, and J. Papkoff Testisin, a Glycosyl-Phosphatidylinositol-Linked Serine Protease, Promotes Malignant Transformation In vitro and In vivo Cancer Res., February 1, 2005; 65(3): 868 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Hobson, S. Netzel-Arnett, R. Szabo, S. M. Rehault, F. C. Church, D. K. Strickland, D. A. Lawrence, T. M. Antalis, and T. H. Bugge Mouse DESC1 Is Located within a Cluster of Seven DESC1-like Genes and Encodes a Type II Transmembrane Serine Protease That Forms Serpin Inhibitory Complexes J. Biol. Chem., November 5, 2004; 279(45): 46981 - 46994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Hoang, J. D'Cunha, M. G. Kratzke, C. E. Casmey, S. P. Frizelle, M. A. Maddaus, and R. A. Kratzke Gene Expression Profiling Identifies Matriptase Overexpression in Malignant Mesothelioma Chest, May 1, 2004; 125(5): 1843 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-J. Hung, I.-W. J. Hsu, J. L. Dreiling, M.-J. Lee, C. A. Williams, M. D. Oberst, R. B. Dickson, and C.-Y. Lin Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1159 - C1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, H. Kobayashi, N. Kanayama, Y. Saga, M. Suzuki, C.-Y. Lin, R. B. Dickson, and T. Terao Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase J. Biol. Chem., April 9, 2004; 279(15): 14899 - 14908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kirchhofer, M. Peek, W. Li, J. Stamos, C. Eigenbrot, S. Kadkhodayan, J. M. Elliott, R. T. Corpuz, R. A. Lazarus, and P. Moran Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1 J. Biol. Chem., September 19, 2003; 278(38): 36341 - 36349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Oberst, B. Singh, M. Ozdemirli, R. B. Dickson, M. D. Johnson, and C.-Y. Lin Characterization of Matriptase Expression in Normal Human Tissues J. Histochem. Cytochem., August 1, 2003; 51(8): 1017 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Oberst, C. A. Williams, R. B. Dickson, M. D. Johnson, and C.-Y. Lin The Activation of Matriptase Requires Its Noncatalytic Domains, Serine Protease Domain, and Its Cognate Inhibitor J. Biol. Chem., July 11, 2003; 278(29): 26773 - 26779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Kang, M. Dolled-Filhart, I. T. Ocal, B. Singh, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer Cancer Res., March 1, 2003; 63(5): 1101 - 1105. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
